Rapid Second-Tier Molecular Genetic Analysis for Congenital Adrenal Hyperplasia Attributable to Steroid 21-Hydroxylase Deficiency
- 1 February 2005
- journal article
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 51 (2), 298-304
- https://doi.org/10.1373/clinchem.2004.042416
Abstract
Background: Neonatal screening for steroid 21-hydroxylase (CYP21) deficiency is performed to identify congenital adrenal hyperplasia (CAH). The immunologic assay for 17α-hydroxyprogesterone (17-OHP) has a high rate of false positives. We assessed the potential for increasing the specificity for CAH by use of a second step involving analysis of the CYP21 gene. Methods: Between January 1999 and December 2003, a total of 810 000 newborns were screened. Of these, 7920 had to be retested because their 17-OHP values were above the cutoff of the assay. Sixty-one had positive 17-OHP values in their recall samples and were diagnosed as having CAH. We used a rapid assay for common mutations of the CYP21 gene to analyze these 61 samples. In a prospective study, 198 consecutive samples that had increased 17-OHP and 100 samples that had normal 17-OHP concentrations were genotyped. Results: Fifty-nine of 61 cases diagnosed as having CAH were confirmed genetically as CYP21 deficiencies. One patient had a 3β-hydroxysteroid dehydrogenase deficiency, and one patient carried no CYP21 mutations. The 198 increased 17-OHP results were designated as false positives after immunologic testing of recall samples. None of these samples exhibited the genetic pattern consistent with CYP21 deficiency. Conclusions: If samples with increased 17-OHP values were screened genetically, the number of retests would decrease by ∼90%, but the overall sensitivity of CAH screening would remain the same. Adding a second-tier genetic step would require a modest increase in costs, but is counterbalanced by fewer recalls, less clinical follow-up, and a reduction in unnecessary worry for families.Keywords
This publication has 19 references indexed in Scilit:
- Molecular genetics of congenital adrenal hyperplasia (21-hydroxylase deficiency): implications for diagnosis, prognosis and treatmentActa Paediatrica, 2007
- Neonatal salt-wasting and 11 β-hydroxylase deficiency in a child carrying a homozygous deletion hybrid CYP11B2 (aldosterone synthase)-CYP11B1 (11 β-hydroxylase)Clinical Genetics, 2004
- Emerging Role for Tandem Mass Spectrometry in Detecting Congenital Adrenal HyperplasiaClinical Chemistry, 2004
- Improved Specificity of Newborn Screening for Congenital Adrenal Hyperplasia by Second-Tier Steroid Profiling Using Tandem Mass SpectrometryClinical Chemistry, 2004
- A Novel A10E Homozygous Mutation in the HSD3B2 Gene Causing Severe Salt-Wasting 3 -Hydroxysteroid Dehydrogenase Deficiency in 46,XX and 46,XY French-Canadians: Evaluation of Gonadal Function after PubertyJournal of Clinical Endocrinology & Metabolism, 2000
- Characterization of Two Novel Homozygous Missense Mutations Involving Codon 6 and 259 of Type II 3 -Hydroxysteroid Dehydrogenase (3 HSD) Gene Causing, Respectively, Nonsalt-Wasting and Salt-Wasting 3 HSD Deficiency DisorderJournal of Clinical Endocrinology & Metabolism, 2000
- Improved precision of newborn screening for congenital adrenal hyperplasia using weight-adjusted criteria for 17-hydroxyprogesterone levelsThe Journal of Pediatrics, 1997
- Improving the efficacy of newborn screening for congenital adrenal hyperplasia by adjusting the cut-off level of 17α-hydroxyprogesterone to gestational ageScreening, 1994
- Mutations in Steroid 21-Hydroxylase (CYP21)Human Mutation, 1994
- Disease expression and molecular genotype in congenital adrenal hyperplasia due to 21-hydroxylase deficiency.JCI Insight, 1992